Clinical consequences of marijuana

Journal of Clinical Pharmacology

Volumn 42, Issue 11 SUPPL., 2002, Pages

  Khalsa, Jag H ^a,c   Genser, Sander ^a   Francis, Henry ^a   Martin, Billy ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Natonal Institute on Drug Abuse   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; NEFAZODONE; TETRAHYDROCANNABINOL;

CANCER RISK; CANNABIS ADDICTION; CARDIOVASCULAR EFFECT; COGNITIVE DEFECT; COUGHING; DRUG EFFECT; EMPHYSEMA; FETOTOXICITY; HEAD CANCER; HEALTH HAZARD; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; LUNG CANCER; LUNG INFECTION; MEDICAL RESEARCH; MUTAGENICITY; NECK CANCER; NONHUMAN; ORTHOSTATIC HYPOTENSION; REVIEW; TACHYCARDIA;

EID: 0036838913     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.2002.tb05997.x     Document Type: Review

References (3)

1. Substance Abuse and Mental Health Services Administration: National Household Survey on Drug Abuse: Main Findings. Rockville, MD: U.S. Department of Health and Human Services, 2002.
2. Johnston LD, O'Malley PM, Bachman JG: Monitoring the Future National Survey Results on Drug Use, 1975-2000: Vol. 1. Secondary School Students. NIH Pub. No. 01-4924. Bethesda, MD: National Institute on Drug Abuse, 2001.
3. Khalsa JH, Gfroerer J: Epidemiology of health consequences of drug abuse among pregnant women. Seminars in Perinatology 1991;15(4):265-270.